Overview
Status
Active
Registry date
2018-04-17
Share capital
5,000.00 PLN
Registered address
ul. Złota 61/100, 00-819 Warszawa, Poland
Electronic delivery address
AE:PL-52928-12749-SRDSB-27
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 89 days late).
- 202518/06/2026
- 202422/05/2025
- 202313/06/2024
- 202207/06/2023
- 202112/10/2022
- 202026/03/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 2.59kMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 19.72MedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 2.54kMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 12.96kMedianUSD 883.09kAverageUSD 31.39m
Industry
Authorized Representatives
Zbigniew Chudy – Management Board Member
Kamil Dawid Kiska – Management Board Member
Manner of representation
The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Zbigniew Chudyage 52 | 50 | $675.31 | 50% |
Kamil Dawid Kiskaage 31 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-11-05.
93 1090 1841 0000 0001 4352 7355
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 7, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
FAQ
The main business activity of Bioleaf Pharma Bis focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on April 17, 2018.
The headquarters is located at: ul. Złota 61, 00-819 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company's revenue reached $2,594.
Yes, in 2025 the company achieved a net profit of $20.
The largest operating cost category falls under other operating costs. This category amounted to $2,544 in 2025, representing 100% of all operating expenses.
Last updated: 2026-06-19